Is tirzepatide in the surpass lane over GLP-1 receptor agonists for the treatment of diabetes?
- PMID: 34724707
- DOI: 10.1093/eurheartj/ehab636
Is tirzepatide in the surpass lane over GLP-1 receptor agonists for the treatment of diabetes?
Comment on
-
Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.Lancet. 2021 Jul 10;398(10295):143-155. doi: 10.1016/S0140-6736(21)01324-6. Epub 2021 Jun 27. Lancet. 2021. PMID: 34186022 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
